Effect of Spraying Pota Crastal Compound and Vast Trivalioum Compound on Growth and Nutritional Status of Superior Grapevines

This study was carried out in three seasons 2019, 2020 and 2021 to examine the effect of spraying Pota crastal or Vast trivolium compounds each at 0.1% either once, twice or thrice on growth and vine nutritional status of Superior grapevines grown under El- Minia region.Application of Pota crastal or Vast trivolium compounds once, twice or thrice each at 0.1% was very effective in enhancing main shoot length, leaf area, wood ripening coefficient, pruning wood weight/ vine, chlorophylls a , b , total chlorophylls, total carotenoids, N, P, K, Mg (as %) Fe, Mn and Zn ( as ppm) of superior grapevines over the control treatment.Using vast trivolium compound was favourable in enhancing some characteristics of vegetative growth and vine nutritional status rather than application of Pota crastal compound. The improvement in the growth characteristics and vine nutritional status was associated with an increase in the number of spraying times from one to three times. The best results with regard to character growth and vine nutritional status of superior grapevines grown under El- Minia region were observed due to treating the vines three times during each season at growth start, just after berry setting and at one month later intervals with vast trivolium compound at 0.1%

Malaria As An Important Cause Of Maternal Mortality In Sudan

This study was performed to highlight the role of malaria in pregnancy as  an important cause  of maternal mortality. It reviewed the previous studies, conference presentations and postgraduate thesis . Malaria found to be the cause of death of 10.26% to 46.7% of MM. The 1998 to 2003 records of maternal deaths of Wad Medani Obstetrics and gynaecology  teaching hospital (WMOGTH) was retrospectively studies (malaria caused death of 8.82% to 39.7% The mean age was 27.57years , most of them were primigravidae and from rural areas.  37.8% of the deaths occured at 28-36 weak of gestation . The mean duration of stay in hospital was (3.22) days. 32.4% of deaths stayed for less than 24 hours This indicated  severe and serious clinical presentations. The main causes of death due to malaria or its complication  were anemae heart failure  (24.3%), cerebral malaria (21.6%) and  circulatory failure (8.1%). Others were pulmonary edema , hyperpyrexia  , puerperal psychosis , abortion , severe epistaxes , cardiac  arrest , black water fever, electrolyte imbalance, and hepatic failure. The study recommended effective prevention of malaria and an intensive care approach in its management

Malaria and Maternal Mortality In Gezira-Sudan

The objectives of this study include:(1) to identify the magnitude of malaria as a cause of maternal mortality (MM) (2) to study the demographic characteristics of MM cases caused by malaria and (3) to identify the actual cause of MM due to malaria. Methods: This is a six years hospital based retrospective review of hospital records of ladies died due to malaria in Wad Medani Teaching Hospital for Obstetrics and Gynaecology (WMTHOG), form1 January 1998 to 31 December 2003. Results: malaria caused 10% to 40% of MM per year. The mean age was 27.57 years, most of them were primigravidae and from rural areas. 37.8% of the deaths occurred between 28 and 36 weak of gestation. The median duration of stay in hospital was two days. However 32.4% of deaths stayed for less than 24 hours that indicated severe and serious clinical presentations. The main causes of death due to malaria or its complication were: anaemia (24.3), cerebral malaria (21.6%), circulatory failure (12.51 ) and renal failure (8.1%). Others were pulmonary oedema , hyperpyrexia  , puerperal psychosis , abortion , severe epistaxis , cardiac  arrest , black water fever, electrolyte imbalance, and hepatic failure. The study recommended effective prevention of malaria and an intensive care approach in its management

Impact of opioid-free analgesia on pain severity and patient satisfaction after discharge from surgery: multispecialty, prospective cohort study in 25 countries

Background: Balancing opioid stewardship and the need for adequate analgesia following discharge after surgery is challenging. This study aimed to compare the outcomes for patients discharged with opioid versus opioid-free analgesia after common surgical procedures.Methods: This international, multicentre, prospective cohort study collected data from patients undergoing common acute and elective general surgical, urological, gynaecological, and orthopaedic procedures. The primary outcomes were patient-reported time in severe pain measured on a numerical analogue scale from 0 to 100% and patient-reported satisfaction with pain relief during the first week following discharge. Data were collected by in-hospital chart review and patient telephone interview 1 week after discharge.Results: The study recruited 4273 patients from 144 centres in 25 countries; 1311 patients (30.7%) were prescribed opioid analgesia at discharge. Patients reported being in severe pain for 10 (i.q.r. 1-30)% of the first week after discharge and rated satisfaction with analgesia as 90 (i.q.r. 80-100) of 100. After adjustment for confounders, opioid analgesia on discharge was independently associated with increased pain severity (risk ratio 1.52, 95% c.i. 1.31 to 1.76; P < 0.001) and re-presentation to healthcare providers owing to side-effects of medication (OR 2.38, 95% c.i. 1.36 to 4.17; P = 0.004), but not with satisfaction with analgesia (beta coefficient 0.92, 95% c.i. -1.52 to 3.36; P = 0.468) compared with opioid-free analgesia. Although opioid prescribing varied greatly between high-income and low- and middle-income countries, patient-reported outcomes did not.Conclusion: Opioid analgesia prescription on surgical discharge is associated with a higher risk of re-presentation owing to side-effects of medication and increased patient-reported pain, but not with changes in patient-reported satisfaction. Opioid-free discharge analgesia should be adopted routinely

Cardio- and reno-protective effect of remote ischemic preconditioning in patients undergoing percutaneous coronary intervention. A prospective, non-randomized controlled trial

Objectives: This study assessed the cardio- and renoprotective effect of remote ischemic Preconditioning (PreC) in patients undergoing percutaneous coronary intervention (PCI). Background: Myocyte necrosis and contrast induced nephropathy (CIN) occur frequently in PCI and are associated with subsequent cardiovascular events. Methods: Two hundred consecutive patients undergoing elective PCI with normal baseline troponin-I (cTnI) values were recruited. Subjects were systematically allocated into 2 groups: 100 patients received PreC (created by three 5 min inflations of a blood pressure cuff to 200 mmHg around the upper arm, separated by 5 min intervals of reperfusion) <2 h before the PCI procedure, and control group (n = 100). Results: The incidence of PCI-related myocardial infarction (MI 4a) at 24 h after PCI was lower in the PreC group compared with control group (41% vs 64%, P = 0.02). Subjects who received PreC had significant trend toward lower incidence of CIN at 72 h after contrast exposure (4 vs. 11, P = 0.05) and less chest pain during stent implantation compared to control group. At 3 months, the major adverse event rate was lower in the PreC group (6 vs. 14 events; P = 0.04). Conclusions: The use of PreC < 2 h before PCI, reduces the incidence of PCI-related MI 4a, tends to decrease the incidence of CIN and improves ischemic symptoms in patients undergoing elective PCI. The observed cardio- and renoprotection appears to confer sustained benefit on reduced major adverse events at 3 month follow-up beyond what is seen with judicious pre- and post-hydration (ClinicalTrials.gov identifier: NCT02313441)

International Nosocomial Infection Control Consortiu (INICC) report, data summary of 43 countries for 2007-2012. Device-associated module

We report the results of an International Nosocomial Infection Control Consortium (INICC) surveillance study from January 2007-December 2012 in 503 intensive care units (ICUs) in Latin America, Asia, Africa, and Europe. During the 6-year study using the Centers for Disease Control and Prevention's (CDC) U.S. National Healthcare Safety Network (NHSN) definitions for device-associated health care–associated infection (DA-HAI), we collected prospective data from 605,310 patients hospitalized in the INICC's ICUs for an aggregate of 3,338,396 days. Although device utilization in the INICC's ICUs was similar to that reported from ICUs in the U.S. in the CDC's NHSN, rates of device-associated nosocomial infection were higher in the ICUs of the INICC hospitals: the pooled rate of central line–associated bloodstream infection in the INICC's ICUs, 4.9 per 1,000 central line days, is nearly 5-fold higher than the 0.9 per 1,000 central line days reported from comparable U.S. ICUs. The overall rate of ventilator-associated pneumonia was also higher (16.8 vs 1.1 per 1,000 ventilator days) as was the rate of catheter-associated urinary tract infection (5.5 vs 1.3 per 1,000 catheter days). Frequencies of resistance of Pseudomonas isolates to amikacin (42.8% vs 10%) and imipenem (42.4% vs 26.1%) and Klebsiella pneumoniae isolates to ceftazidime (71.2% vs 28.8%) and imipenem (19.6% vs 12.8%) were also higher in the INICC's ICUs compared with the ICUs of the CDC's NHSN